Evidence map›Paper›PMID 39833208›Full record

ArticleNPJ vaccines2025

Validation of a multiplexed immunoassay for immunological analysis of pre erythrocytic malaria vaccines.

L K Stockdale, S Provstgaard-Morys, D Bellamy, D Woods, K Rapi, A Bajer, B Hollingdale, O Muñoz, S Malik, A V S Hill and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

L K Stockdale *Jenner Institute, University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford, OX3 7DQ, UK. lisa.stockdale@ndm.ox.ac.uk.ORCID http://orcid.org/0000-0002-2576-8783
S Provstgaard-Morys *Jenner Institute, University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford, OX3 7DQ, UK.
D BellamyJenner Institute, University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford, OX3 7DQ, UK.
D WoodsJenner Institute, University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford, OX3 7DQ, UK.
K RapiJenner Institute, University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford, OX3 7DQ, UK.
A BajerJenner Institute, University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford, OX3 7DQ, UK.
B HollingdaleJenner Institute, University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford, OX3 7DQ, UK.
O MuñozJenner Institute, University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford, OX3 7DQ, UK.
S MalikJenner Institute, University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford, OX3 7DQ, UK.
A V S HillJenner Institute, University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford, OX3 7DQ, UK.ORCID http://orcid.org/0000-0003-0900-9629
K J EwerJenner Institute, University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford, OX3 7DQ, UK.ORCID http://orcid.org/0000-0001-9827-9836

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The primary immunological readout for clinical trials of R21/MatrixM™ malaria vaccine, is total IgG antibody specific to the central four amino acid NANP repeat region of the circumsporozoite protein. A multiplexed assay, which includes NANP, was developed and validated for four antigens representing components of the R21 immunogen. Initial assay optimisation included validation of the HBsAg international standard. Further validation performed in Oxford covered intra and inter-assay, and inter-operator variability, accuracy of QC and standard curve material, and included bridging to a singleplex NANP6 ELISA. The assay was shown to be robust and specific, with a broad dynamic range. We report a strong linear relationship between NANP6 IgG as measured by the singleplex ELISA and the multiplexed assay with rho values of 0.89 and 0.88 for two separate clinical trials (both p < 0.0005). This assay can be used to measure antibodies specific to the CSP NANP repeat region, CSP C-term region, full length R21 and HBsAg.

Identifiers

PMID39833208
PMCPMC11747258

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.